22 October 2020 - CADTH has finalised its assessment of eculizumab for adult patients with refractory generalised myasthenia gravis.

The CADTH Canadian Drug Expert Committee has recommended that eculizumab be reimbursed for the treatment of adults with refractory generalised myasthenia gravis only if certain conditions are met.

One of the conditions is as expected, a reduction in price.

Read CADTH final recommendation for eculizumab